Henri Termeer joins Prosensa as Strategic Advisor

Archive

« Older Entries Newer Entries »

Curetis AG Chooses Mediphos as Exclusive Distribution Partner for the Netherlands Wednesday, September 26th, 2012

Partners prepare market launch and clinical evaluation project Holzgerlingen, Germany, September 26, 2012 -- Curetis AG today announced that Curetis and Mediphos have closed an exclusive distribution agreement for the [...]

Curetis and Heraeus Medical Collaborate on the Development of New Unyvero™ Diagnostic Cartridge Thursday, September 20th, 2012

Joint development of cartridge for orthopaedics, wound and surgery infections Holzgerlingen and Wehrheim (Germany), September 20, 2012 -- Curetis AG and Heraeus Medical GmbH have signed a collaboration agreement to jo [...]

Pasteuria Bioscience to be Acquired by Syngenta Thursday, September 20th, 2012

Amsterdam and Boston, September 20, 2012 - LSP is pleased to announce that Syngenta has agreed to acquire Pasteuria Bioscience, Inc., a US-based biotechnology company. Since 2011 Syngenta and Pasteuria have had an exclus [...]

Three LSP portfolio companies nominated to the 2012 Fierce 15 list Wednesday, September 19th, 2012

Amsterdam, September 19, 2012 – Life Sciences Partners (LSP), the European health care investment group, today announced the nomination of three of its portfolio companies to the prestigious FierceBiotech’s 2012 Fier [...]

Celladon Corporation Named a 2012 Fierce 15 Company by FierceBiotech Wednesday, September 19th, 2012

San Diego, California, September 19, 2012/PRNewswire/ -- Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, today announced th [...]

Hybrigenics starts Phase II clinical trial of inecalcitol in chronic lymphocytic leukemia Tuesday, September 11th, 2012

Paris, 11 September 2012 – Hybrigenics (ALHYG), a bio-pharmaceutical company listed on Alternext (NYSE-Euronext) in Paris, with a focus on research and development of new treatments against proliferative diseases, toda [...]

Celladon Corporation Announces First Patient Dosed in CUPID Phase 2b Trial of MYDICAR® for Advanced Heart Failure Wednesday, August 29th, 2012

San Diego, California, August 29, 2012/PRNewswire/ -- Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, announced today that [...]

Celladon Corporation Receives Patent from United States Patent and Trademark Office Thursday, July 19th, 2012

-Patent will further expand intellectual property protection for MYDICAR® – a first in class drug under clinical evaluation for advanced heart failure - San Diego, California, July 19, 2012/PRNewswire/ -- Celladon Co [...]

Curetis AG Signs Distribution Deal in Middle East with ATC Wednesday, July 18th, 2012

Holzgerlingen, Germany, July 18, 2012 -- Curetis AG, an innovative molecular diagnostics company focusing on the development and commercialization of in-vitro diagnostic products for infectious diseases, today announced [...]

Pronota’s Risk Stratification Test Breaks New Ground in the Early Detection of Pre-term Pre-eclampsia Cases in SCOPE Consortium Study Monday, July 9th, 2012

Ghent, Belgium, July 9, 2012. Pronota NV, a company dedicated to the development of best-in-class diagnostics for early detection of life-threatening conditions, announced today that it has successfully validated its mid [...]

« Older Entries Newer Entries »

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

back to archive overview

Archive

Archive

MONTHLY REPORTS